Delivery Order SPE2DB20D3104-SPE2DB25FW0M1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $35,990.01. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) under a firm fixed-price contract valued at $1,664.74. The award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-competitive delivery order without set-aside designation. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania, the company's corporate...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at approximately $29,900 on September 23, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, reflecting the contractor's ability to compete in open procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for Ondansetron ODT 4 mg tablets (30-count) valued at $4,536.73 under a firm fixed-price contract type. The award was made on August 22, 2025, with an ultimate completion date of August 25, 2025. This is a non-set-aside award, indicating it was competitively awarded. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,347.84 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of September 4, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $7,208.69. This competitively awarded, firm fixed price delivery order is scheduled for completion by September 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,413.45 for Ondansetron ODT 4 mg tablets (30-count supply) on August 1, 2025, with a completion date of August 4, 2025. This non-competitive, firm fixed price delivery order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a continuation of the company's extensive pharmaceutical supply relationship with DLA, supporting federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $8,939.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $18,470.50 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Ondansetron ODT 4 mg tablets in a 30-count quantity. This firm fixed-price delivery order, valued at $7,580.15, represents a competitively awarded non-set-aside contract with an ultimate completion date of August 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB25FW0M1Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a contract ceiling value of $2,427.79. The award was made on September 25, 2025, with an ultimate completion date of September 26, 2025, under a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary pharmaceutical distribution operations. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through December 2026. AmerisourceBergen serves as a critical pharmaceutical supplier to the Defense Health Agency and other federal healthcare systems through this comprehensive global pharmaceutical support vehicle. The company's federal contract portfolio demonstrates its extensive capability to deliver pharmaceuticals and medical supplies across multiple therapeutic domains to military and veteran healthcare systems through competitively awarded contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 9/25/25 |